Veracyte, Inc. (VCYT)

33.22 +0.25 (+0.76%) As of 10:50AM EDT. Market open.

Veracyte, Inc.

6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 243 6300
https://www.veracyte.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 815

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Marc A. Stapley	CEO & Director	1.55M	N/A	1970
Ms. Rebecca Chambers	Executive VP & CFO	901.49k	N/A	1978
Dr. Phillip G. Febbo M.D.	Chief Scientific & Medical Officer	657.74k	N/A	1966
Ms. Annie McGuire	Executive VP, General Counsel & Chief People Officer	791.72k	N/A	1981
Dr. John Leite Ph.D.	Chief Commercial Officer for CLIA Business	1.53M	N/A	1972
Mr. Jonathan Wygant	VP & Chief Accounting Officer	N/A	N/A	1971
Mr. Steven French	Senior VP & Chief Information Officer	N/A	N/A	N/A
Ms. Karen Possemato	Senior Vice President of Corporate Marketing, Communications & Commercial Operations	N/A	N/A	N/A
Mr. Robert Brainin	Executive VP & Chief Business Officer	N/A	N/A	1972
Ms. Corinne Danan	Senior Vice President	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Corporate Governance

Veracyte, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 5. The pillar scores are Audit: 7; Board: 3; Shareholder Rights: 4; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.